Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00254579 · ClinicalTrials.gov registry record · Phase 2
Study of CP-675,206 in Refractory Melanoma
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 251
- Enrollment target
NCT00254579 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 251 participants.
The verdict
NCT00254579, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 251 participants
- Enrollment target
Study Summary
CP-675,206 is a fully human monoclonal antibody (mAb). It binds to the CTLA4 molecule, which is expressed on the surface of activated T lymphocytes. CP-675,206 is thought to stimulate patients' immune systems to attack their tumors. CP-675,206 is not expected to have a direct effect on tumor cells. CP-675,206 been shown to induce durable tumor responses in patients with metastatic melanoma in Phase 1 and Phase 2 clinical studies.
Interventions
- DRUG CP-675,206
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 251 participants |
| Start Date | 2005-12 |
| Est. Completion | 2009-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00254579
The ClinicalTrials.gov registry entry for NCT00254579 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 251 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CP-675,206 is the first listed.
NCT00254579 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00254579 about?
NCT00254579 is a clinical study titled "Study of CP-675,206 in Refractory Melanoma". CP-675,206 is a fully human monoclonal antibody (mAb). It binds to the CTLA4 molecule, which is expressed on the surface of activated T lymphocytes. CP-675,206 is thought to stimulate patients' immune systems to attack their tumors. CP-675,206 is not expected to have a direct effect on tumor cells. ...
What is the current status of trial NCT00254579?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 251 participants. The study started on 2005-12. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00254579?
The interventions under investigation include: CP-675,206 (DRUG).
Who is sponsoring clinical trial NCT00254579?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.